Johnson & Johnson (NYSE:JNJ) announced plans to remove its LINX Reflux Management System from markets outside the United States, according to a Bloomberg report on Tuesday.
JNJ shares were up 0.9% in premarket trading.
The company said the withdrawal, scheduled to begin in March, is for commercial reasons and not linked to any safety or effectiveness concerns, Bloomberg noted, citing a letter sent to physicians.
The LINX device is intended for patients with chronic gastroesophageal reflux disease (GERD), a condition in which stomach contents flow back into the esophagus. The system uses a flexible ring of small magnets placed around the lower esophageal muscles, helping to keep them closed and prevent acid reflux.
Johnson & Johnson has not provided further details on why the product will be withdrawn internationally while remaining available in the U.S.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.